Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human CD82/Kai-1 Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 2 publications
Supplier: R&D Systems MAB4616
This item is not returnable.
View return policy
Description
CD82/Kai-1 Monoclonal specifically detects CD82/Kai-1 in Human samples. It is validated for Flow Cytometry, CyTOF-ready.Specifications
CD82/Kai-1 | |
Monoclonal | |
LYOPH | |
Flow Cytometry 2.5 ug/10^6 cells, CyTOF-ready | |
AAH01821 | |
CD82 | |
NS0 mouse myeloma cell line transfected with human CD82/Kai-1 Met1-Tyr267 Accession # AAH01821 | |
100 μg | |
Primary | |
Detects human CD82/Kai-1. Stains human CD82/Kai-1 transfectants but not irrelevant transfectants. | |
Human | |
Purified |
Flow Cytometry, CyTOF | |
423524 | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
CD82, CD82 antigenC33, CD82 molecule, IA4, IA4C33 antigen, Inducible membrane protein R2, KAI1, KAI1GR15, kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyteantigen, antigen detected by monoclonal and IA4)), Metastasis suppressor Kangai-1, R2, SAR2, SAR2tetraspanin-27, ST6, ST6tspan-27, Suppressor of tumorigenicity 6 protein, Tetraspanin-27, Tspan-27, TSPAN27, TSPAN274F9 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
3732 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction